Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Mind Medicine (MNMD)
NASDAQ:MNMD
Holding MNMD?
Track your performance easily
MNMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.49 - $12.22
Previous CloseN/A
Volume779.86K
Average Volume (3M)1.24M
Market Cap
$477.39M
Enterprise Value$185.59M
Total Cash (Recent Filing)$80.09M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Apr 08, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.08
Shares Outstanding73,331,690
10 Day Avg. Volume1,463,593
30 Day Avg. Volume1,241,029
Standard Deviation1.35
R-Squared0.07
Alpha0.28
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-6.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.39
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.98
Forecast
1Y Price Target
$24.29Price Target Upside273.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Mind Medicine News
PremiumCompany Announcements
MindMed Begins Phase 3 LSD Study for Anxiety
Ownership Overview
2.48% Insiders
5.47% Mutual Funds
0.16% Other Institutional Investors
83.34% Public Companies and Individual Investors
MNMD FAQ
What was Mind Medicine’s price range in the past 12 months?
Mind Medicine lowest stock price was $3.49 and its highest was $12.22 in the past 12 months.
What is Mind Medicine’s market cap?
Mind Medicine’s market cap is $477.39M.
When is Mind Medicine’s upcoming earnings report date?
Mind Medicine’s upcoming earnings report date is Apr 08, 2025 which is in 80 days.
How were Mind Medicine’s earnings last quarter?
Mind Medicine released its earnings results on Nov 07, 2024. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.277 by $0.097.
Is Mind Medicine overvalued?
According to Wall Street analysts Mind Medicine’s price is currently Undervalued.
Does Mind Medicine pay dividends?
Mind Medicine does not currently pay dividends.
What is Mind Medicine’s EPS estimate?
Mind Medicine’s EPS estimate is -0.29.
How many shares outstanding does Mind Medicine have?
Mind Medicine has 73,331,690 shares outstanding.
What happened to Mind Medicine’s price movement after its last earnings report?
Mind Medicine reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.277. Following the earnings report the stock price went up 12.899%.
Which hedge fund is a major shareholder of Mind Medicine?
Currently, no hedge funds are holding shares in MNMD
---
Mind Medicine Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$24.29 (273.12% Upside)
$24.29 (273.12% Upside)
Blogger Sentiment
Bullish
MNMD Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Bought Shares
Worth $17.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.2%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
69.09%
12-Months-Change
Fundamentals
Return on Equity
-37.30%
Trailing 12-Months
Asset Growth
125.91%
Trailing 12-Months
Company Description
Mind Medicine
Mind Medicine (MNMD) is a biotechnology company focused on developing psychedelic-inspired therapies to address mental health and addiction disorders. The company operates within the pharmaceutical and biotechnology sectors, aiming to transform mental health treatment through innovative research and clinical trials. Its core products include novel drug candidates designed to treat conditions such as anxiety, depression, and opioid addiction, leveraging the therapeutic potential of psychedelics.
---
MNMD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted MindMed's strong financial position and progress towards Phase III trials, while also acknowledging rising R&D expenses and a net loss. The sentiment leans towards positive due to the company's strong cash reserves and clear roadmap for advancing clinical trials.Read More>---
MNMD Stock 12 Month Forecast
Average Price Target
$24.29
▲(273.12% Upside)
Technical Analysis
Best Analysts Covering MNMD
1 Year
1 Year Success Rate
11/20 ratings generated profit
1 Year Average Return
+32.63%
reiterated a buy rating 2 months ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 55.00% of your transactions generating a profit, with an average return of +32.63% per trade.
---